Manuscript Details

Manuscript number	ACTROP_2016_119
Title	Combination therapy in the management of giardiasis: what laboratory and clinical studies tell us, so far
Article type	Review Article

Abstract

Treatment failures in patients suffering from giardiasis is not uncommon feature. The most frequent approach in these cases is to treat these patients with longer repeated courses and/or higher doses of the primary therapy, or using drugs from a different class to avoid potential cross-resistance. However, a higher rate of adverse events may limit this strategy. In this context, combination therapy (CT) is emerging as a valuable option against refractory giardiasis. In the attempt to evaluate the benefits of CT, a number of experimental studies, clinical series, and randomized clinical trials (RCTs), as well as several veterinary studies have been performed, with varying results. Here, we present a critical analysis of the available information regarding CT for the treatment of Giardia infection, as well as the authors' opinion with respect to its use. RCTs of combination therapy are limited and the optimal combinations and administration strategies need yet to be clarified. Analyses of the cost-effectiveness and RCTs of CTs for Giardia infection are required to assess the role of these drugs for the control of giardiasis, mainly in the case of treatment failures linked to suspected drug tolerance are the case.

Keywords Giardia; giardiasis; combination therapy; 5-nitroimidazoles; albendazole; metronidazole; nitazoxanide; quinacrine; tinidazole

Corresponding Author Angel Escobedo

Corresponding Author's Institution Hospital "Pedro Borrás"

Order of Authors Angel Escobedo, Marco Lalle, Nana Hrastrnik, Alfonso J. Rodriguez-Morales, Enrique Castro-Sánchez, SERGIO CIMERMAN, Pedro Almirall, Jony Jones

Suggested reviewers Theodore Nash, Rodney Adam, Rogelio López-Velez

Submission Files Included in this PDF

File Name [File Type]

Highlights.doc [Highlights]

scan.jpg [Cover Letter]

Combination.16Junio.doc [Manuscript File]

Rebuttal to comments from the reviewers.doc [Response to Reviewers]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

Highlights

Treatment failures are not uncommon in giardiasis.

Published studies have shown combination therapy in giardiasis to be safe and effective.

Observations encourage the study of combinations of metronidazole with albendazole or quinacrine.

Combination therapy could be a useful alternative in the case of treatment failures linked to suspected drug tolerance.

Havana, April 25, Cuba

Dear editor

Enclosed, please find a copy of the review article "Combination therapy in the management of gonorrhea: what laboratory and clinical studies tell us, so far". This review is original and is not under consideration for publication elsewhere. This version of the manuscript has been read and approved by all authors, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the copyright-holder. There is no conflict of interest to declare.

* Angel A. Escobedo

* Marco Lillo

Manel I. Hinojosa

Alfonso J. Rodríguez Morales

Antônio Castro-Sánchez

Sergio Cárdenas

Padre Almirall

Ismael Juncos

All the best,

Dr. Escobedo

Assistant, Pharmacy Hospital "Patria Roja"

Havana City

Cuba

and I enclose the informed consent

* Corresponding authors

Combination therapy in the management of giardiasis: what laboratory and clinical studies tell us, so far

Angel A. Escobedo^{a,b,c,*†}, Marco Lalle^{d,*†}, Nana I. Hrastnik^e, Alfonso J. Rodríguez-Morales^{b,c,f,g}, Enrique Castro-Sánchez^h, Sérgio Cimerman^{c,i}, Pedro Almirall^{c,j}, Jony Jones^k

^a *Department of Microbiology and Parasitology, Academic Paediatric Hospital “Pedro Borrás”, F. N°616, esquina a 27. Plaza. La Habana, 10400, Cuba*

^b *Working Group on Zoonoses, International Society for Chemotherapy, Aberdeen, United Kingdom*

^c *Committee on Clinical Parasitology, Panamerican Association for Infectious Diseases (Asociación Panamericana de Infectología)*

^d *Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy*

^e *University of Nova Gorica, Vipavska 13, 5000 Nova Gorica, Slovenia*

^f *Research Group Public Health and Infection, Faculty of Health Sciences, Universidad Tecnológica de Pereira (UTP), Pereira, Risaralda, Colombia*

^g *Committee on Zoonoses and Hemorrhagic Fevers of the Colombian Association of Infectious Diseases (Asociación Colombiana de Infectología, ACIN), Bogotá, Colombia*

^h *Centre for Infection Prevention and Management, Imperial College London, Faculty of Medicine, Commonwealth Building, Du Cane Road, London W12 0NN, United Kingdom*

ⁱ *Institute of Infectious Diseases “Emilio Ribas”, Rua Zacarias de Gois, 966/41, 04610-002, SP, São Paulo, Brazil*

^j *Analysis and Health Trends Unit, Unidad Municipal de Higiene, Epidemiología y Microbiología, Calle 8 esquina a 17, Plaza, La Habana, Cuba*

^k *Faculty of Medicine “Manuel Fajardo” Zapata esquina a C, Plaza, La Habana, CP 10400, Cuba*

Running head: Combination therapy in giardiasis

[†]Authors contribute equally.

*Address for correspondence: Angel A. Escobedo, Department of Microbiology, Paediatric Academic Hospital “Pedro Borrás”, F. N°616, Plaza. Havana City, 10400, Cuba. email: escobedo@infomed.sld.cu; Marco Lalle, Department of Infectious, Parasitic and Immunomediated Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy, email: marco.lalle@iss.it

Treatment failures in patients suffering from giardiasis are not uncommon feature. The most frequent approach in these cases is to treat these patients with longer repeated courses and/or higher doses of the primary therapy, or using drugs from a different class to avoid potential cross-resistance. However, a higher rate of adverse events may limit this strategy. In this context, combination therapy (CT) is emerging as a valuable option against refractory giardiasis. In the attempt to evaluate the benefits of CT, a number of experimental studies, clinical series, and randomized clinical trials (RCTs), as well as several veterinary studies have been performed, with varying results. Here, we present a critical analysis of the available information regarding CT for the treatment of *Giardia* infection, as well as the authors' opinion with respect to its use. RCTs of combination therapy are limited and the optimal combinations and administration strategies need yet to be clarified. Analyses of the cost-effectiveness and RCTs of CTs for *Giardia* infection are required to assess the role of these drugs for the control of giardiasis, mainly in the case of treatment failures linked to suspected drug tolerance are the case.

Keywords: *Giardia*, giardiasis, combination therapy, 5-nitroimidazoles, albendazole, metronidazole, nitazoxanide, quinacrine, tinidazole

1. Overview on giardiasis and its treatment options

The flagellated protozoan *Giardia duodenalis* (syn. *G. lamblia* and *G. intestinalis*, from now referred as *Giardia*) is an intestinal parasite widespread globally, in temperate and tropical locations, especially where sanitary conditions are suboptimal. It affects mammals, including human, pets and livestock, by inhabiting the upper part of the small intestine. Eight morphologically homogeneous but genetically distinguishable groups, or assemblages (A to H), have been isolated from different mammalian species ([Ryan and Cacciò, 2013](#)). Assemblages A and B are found in human and other animals, being considered zoonotic, whereas the other assemblages display host specificity and do not infect humans (C and B in dog, F in cat, E in hooved animal, G in rodents and H in sea mammals).

In human, *Giardia* is the most common intestinal parasitic protozoan diagnosed worldwide and it is the causative agent of giardiasis, an acute and chronic enteritis. Giardiasis may occur without clinical manifestations, although in many cases, it causes a self-limited and often persistent illness that is characterized by acute or chronic diarrhea, abdominal pain, nausea, vomiting, flatulence and weight loss ([Escobedo et al., 2010](#); [Lalle, 2010](#)). Although giardiasis can affect all age groups, children are at higher risk. *Giardia* infection in children has been associated with lower serum level of zinc, iron, and vitamins (A, B12 and folate), despite similar anthropometric indicators among infected and non-infected individuals ([Olivares et al., 2002](#); [Demirci et al., 2003](#); [Quihui-Cota et al., 2008](#)), and in early childhood, failure to thrive and poor cognitive function ([Berkman et al., 2002](#); [Celiksöz et al., 2005](#)). Other long-term health consequences of giardiasis have been also documented, including chronic fatigue and post-infectious irritable bowel syndrome ([Persson et al., 2015](#)).

During the last 60 years of the past century, a number of anti-giardial drugs have been introduced and are still in use. The 5-nitroimidazole (5-NI) derivatives remain the most frequently prescribed drugs, including metronidazole (MTZ), tinidazole (TNZ) and secnidazole (SNZ). Other drugs include: the benzimidazole derivatives, albendazole (ABZ) and mebendazole (MBZ); the acridine derivative, quinacrine (QC); the nitrothiazolide, nitazoxanide (NTZ); the nitrofuran, furazolidone (FRZ); and the aminoglycoside, paromomycin (PRM). The advent of these drugs has been accompanied by a rise in the number of scientific publications concerning their pharmacology and clinical use ([Escobedo et al., 2015](#)). Despite their efficacy, treatment with these drugs is associated with several adverse effects, i.e., headache, metallic or bitter taste in mouth, nausea, vomiting, diarrhoea, dizziness, general body discomfort, loss of appetite, etc ([Escobedo and Cimerman, 2007](#); [Escobedo et al., 2010](#); [Lalle, 2010](#)). These bothersome side effects maybe hardly tolerated by a number of patients, whereas medical contraindications may limit the use of some of them in particular cases, as in pediatrics, where their dose requirements make difficult the administration of tablet formulations to children.

Follow-up of patients after treatment is paramount to evaluate the response to anti-giardial drugs. Some individuals may experience treatment failure, despite having received successive courses of therapy, usually reported effective in curing giardiasis ([Escobedo and Cimerman, 2007](#); [Escobedo et al., 2010](#); [Lalle, 2010](#)). Potential reasons of non-effectivity may be associated to: poor patient compliance ([Shepherd and Boreham, 1989](#)), poor medicines quality, including spurious, falsely labeled, falsified, counterfeit medicines, chemical and/or physicochemical instability, inappropriate storage and transport, and poor quality control during manufacturing and importing medicines ([Heyman and Williams, 2011](#)), variation in the pharmacokinetics of drugs,

inactivation of the drug by superinfection with other organisms, reinfection, inadequate drug levels, immunosuppression, resistance to the drug, sequestration in the gallbladder or pancreatic ducts (Boreham et al., 1987; Nash et al., 2001; Robertson et al., 2010), and unknown reasons (Nash et al., 2001; Robertson et al., 2010), including the possibility of invasive giardiasis (Martínez-Gordillo et al., 2014). Refractory giardiasis may be clinically challenging, especially when reinfection, noncompliance, poor quality of medicines and inadequate drug levels are not the causes.

One of the therapeutic strategies to overcome treatment failures with a single anti-giardial drug regimen is to proceed with additional courses of the same drugs increasing the dose and/or duration of the treatment (Mørch et al., 2008; Yadav et al., 2014). Alternatively, since anti-giardial drugs may vary in their modes of action as well as differences in resistance mechanisms may occur (Table 1), drugs combination might exert synergistic effects. Consequently, it is quite common to treat certain groups of patients with combinations of these medications to maximize therapeutic benefit. If anti-giardial combination therapy (CT) provides an added benefit, an increased response rate is then expected. However, it should be noted that CT could also lead to antagonism for some drug combinations, enhanced toxicity, and significant additional costs.

CT has been successfully applied for the treatment of infectious and noninfectious diseases (i.e., tuberculosis, leprosy, malaria, cancer and asthma). A similar approach has been also introduced for management of giardiasis; when monotherapy has provided inadequate parasitological benefit, supplemental drugs have been added. CT in giardiasis may rely on drug repurposing and/or on combination of the already known anti-giardial agents to provide a synergistic approach.

As CT has recently gained widespread acceptance for refractory cases of giardiasis, it is

important to critically evaluate the current CT based on the evidences before endorsement.

2. Articles' search methods

A thorough PubMed search was conducted on CTs for *Giardia* infection. Journal articles spanning the time period between January 1966 and February 2016 were reviewed. Literature searches were restricted to the English, Italian, Spanish and Portuguese languages, and included combinations of the following terms: combination therapy, *Giardia* and giardiasis. All pertinent *in vitro*, randomized controlled trials (RCTs), and retrospective analyses were included. References from retrieved articles were also manually scanned for additional relevant publications.

3. Results

This review presents a detailed account of the published data on the use of CT in giardiasis. In the attempt to evaluate the benefits of anti-giardial CT, a number of experimental studies, case reports, clinical series, and RCTs have been performed, with varying results. In this review, we summarize the available data. It should be taken into account that, covering a period of almost 40 years, the studies reviewed herein varied both in terms of accuracy and methodologies, especially in evaluating drug treatment outcomes. In this perspective, a rigorous comparison of experimental data was not feasible.

3.1. Efficacy and safety of anti-giardial combination therapy

3.1.1. Preclinical Studies

There are various experimental studies on combinations of different drugs for the treatment of giardiasis to evaluate anti-giardial susceptibility and interactions between anti-giardials. These include *in vitro* studies and studies in animals and animal models.

All documented *in vitro* investigations have been performed with laboratory established cultures of *Giardia* trophozoites isolated from human patients and belonging to the zoonotic assemblage A. Experimental infections of animals were instead conducted either with the aforementioned human isolated or using cysts freshly isolated from naturally infected animal, often without any information on genotype (zoonotic or host-specific). Similarly, no assemblage information was available for naturally infected animal.

3.1.1.1. *In vitro* studies

Due to the wide prescription of MTZ as anti-giardial chemotherapeutic, several *in vitro* evaluation of its effect in addition to known or potential anti-giardial drugs were conducted. Two studies focused on the MTZ/QC combination ([Gillin and Diamond, 1981](#); [Smith et al., 1982](#)). In the first one the *Giardia* Portland-1 trophozoites, isolated from an individual with diarrhoea, were used. The combined drugs had an additive anti-giardial effect, being similar to the sums of their separate effects, and not synergic ([Gillin and Diamond, 1981](#)). In the other study, drug susceptibility assays were performed on *Giardia* trophozoites (WB) isolated from a patient who suffered of chronic symptomatic giardiasis and was cured by a combination of QC and MTZ, despite previous seven separate courses of either QC or MTZ alone. Compared to other isolates of *Giardia*, WB displayed a similar sensitivity to either drug alone but was more sensitive to QC/MTZ combination, suggesting that persistence of the infection was not ascribable to unique drug resistance properties of the WB isolate but to a lower cytotoxic phenotype ([Smith et al., 1982](#)).

The activity of MTZ associated to pyrantel pamoate (PP) was also investigated *in vitro*. PP is an inhibitor of cholinesterases commonly used as deworming drug in veterinary ([Kopp et al., 2008](#)). It has been proven to be effective also in the treatment of giardiasis

in small animals ([Barr et al., 1998](#)), being able to inhibit the growth of *Giardia* Portland-1 trophozoites ([Campanati et al., 2001](#)). A significant synergic effect on *in vitro* growth inhibition of *Giardia* WB trophozoite was observed combining different concentration of MTZ and PP. The stronger effect was achieved with drug combination containing lower sub-optimal doses of both compounds all showing a fractional inhibitory concentration index (FICI) <0.5 ([Hausen et al., 2011](#)). Furthermore, the combinations of MTZ and PP induced a reduction of parasite adhesion on rat intestinal epithelial cells (IEC-6 line) without affecting the viability of untreated cell line ([Hausen et al., 2011](#)). Tetrahydrolipstatin (known as orlistat), a lipase inhibitor approved for the treatment of obesity, has also been tested in combination with MTZ ([Hahn et al., 2013](#)). Orlistat alone has a giardiacidal effect *in vitro*, showing inhibition of *Giardia* replication and growth, with a IC₅₀ lower than MTZ, on both WB and 14-03/F7 isolates, the latter obtained from a patient with MTZ refractory giardiasis. When orlistat and MTZ were used together, they showed an additive inhibitory effect. The analysis of the combination effects is in favor of an independent mode of action of the two drugs thus envisaging a beneficial effect for patients in the case of a combined therapeutic application ([Hahn et al., 2013](#)).

Also benzimidazoles were tested in combination with compounds belonging to different classes, but all showing structural and electronic similarities with the benzimidazole core. Two 4-R-ethyl-phenylcarbamate derivatives (IRE-6A and IRE-7B) have shown a modest anti-giardial activity against *Giardia* Portland-I isolate (ABZ-susceptible) and its induced ABZ-resistant clone, although the drug potency was slightly reduced for the latter one ([Jiménez-Cardoso et al., 2004](#)). The combined treatment with ABZ, at its MIC₅₀ concentration, and each compound at various concentration resulted in a synergistic lethal effect also on the ABZ-resistant clone. The drug combination was 5 to

9 times less toxic against CHO cell line (Jiménez-Cardoso et al., 2004). Similarly, synthetic derivatives of imidazo[1,2-a]pyridines and pyrimidines also exert growth inhibitory activity on *Giardia* WB trophozoite, without cytotoxicity on Vero cell line.²⁸ The combination of ABZ with each of the three most potent derivatives, all at their respective IC₅₀, exerted a synergic effect increasing the overall anti-giardial activity as the result of pharmacological interaction (Velázquez-Olvera et al., 2016).

In vitro cytotoxicity and adherence inhibition were evaluated for *Giardia* Portland-1 and BRIS/82/HEPU/41 isolates using dyadic combinations of azithromycin and doxycycline, two antibiotics known to inhibit bacterial protein synthesis, and two anti-giardial nitro compound, TNZ and FRZ, and the antimalarial mefloquine (Crouch et al., 1990). All drug combinations exerted an additive inhibitory effect on the parasite growth, independent on the isolate. On the contrary, the combination of azithromycin-FRZ, doxycycline- mefloquine, doxycycline-TNZ and mefloquine-TNZ provided evidence of a synergistic activity that hampered parasite adherence (Crouch et al., 1990), in agreement with independent mechanisms of action of these compounds.

3.1.1.2. Treatment in animals and animal models

As previously pointed out, human infection is caused by the *Giardia* zoonotic assemblages A and B. Although epidemiological evidences suggest that *Giardia* infection in humans is often due to anthroponotic spread, animals, especially farm and companion animals, can be sources of human infection and vice-versa, being infected with both zoonotic or host-specific assemblages (Ryan and Cacciò, 2013; McDowall et al., 2011). Several studies reported on high prevalence of *Giardia* in stool samples of companion animals (i.e. cats and dogs) (Bouzig et al., 2015). Pets are prevalently infected with host-specific assemblages (C and D in dogs, F in cats), but the zoonotic A and B assemblages were also reported in several settings, and may prevail in

environments commonly contaminated with cysts from the feces of humans or other animals ([Thompson 2004](#); [Ballweber et al., 2010](#)). Although their role as reservoir and the associated risk for their owners is unclear, their treatment to potentially reduce the risk of transfer to human beings cannot be ignored. To provide a complete overview of CT data from naturally infected animals or with animals experimentally infected with *Giardia* isolates, either from human or animal origin were included.

Several studies have been performed on naturally infected dogs to evaluate the efficacy of different dosages of the combination of three compounds (FPP combination): febantel, a prodrug *in vivo* metabolized to the benzimidazoles fenbendazole and oxyfenbedazole ([Mc Kellar and Scott, 1990](#)); pyrantel; and praziquantel (PZQ), a broad-spectrum anthelmintic against parasitic trematodes and cestodes ([Andrews et al., 1983](#)). In the first study, 3 groups of 5 beagles each, having natural infection with *Giardia* and a median age of 9 months, were administered with the United States (US) FPP formulation of combination tablets (68 mg of PZQ, 68 mg of PP, and 340.2 mg of febantel) daily for 1 or 3 consecutive days, whereas a control group received placebo tablets. Faecal samples were all negative for *Giardia* cysts only in the group treated for 3 days and no side effects were reported (e.g. vomit, diarrhoeic faeces) ([Barr et al., 1998](#)). Similar results were also reported in a subsequent study ([Payne et al., 2002](#)), in which 16 beagles, 7 to 10 months old, were treated daily up to 5 days and cyst shedding was evaluated for up to 24 days. Co-administration of a *Giardia* vaccine with the FPP combination tablets did not improve the treatment efficacy ([Payne et al., 2002](#)). The European formulation of FPP (50 mg PZQ, 144 mg pyrantel embonate, 150 mg febantel per tablet), registered for the treatment of several canine helminthiasis, was also evaluated on adult dogs infected with *Giardia*. The combination tablets was effective in removing *Giardia* cysts from the faeces when administered once at double the

recommended dosage, or for two or three consecutive days, without adverse side effects (Giangaspero et al., 2002). A prolonged treatment up to 5 days was shown to not be statistically better than treatment for three consecutive days (Montoya et al., 2008). In a larger survey on adult dogs naturally infected with several parasite, including *Giardia*, a similar therapeutic efficacy was demonstrated comparing a treatment once daily for 3 days of febantel-pyrantel-PZQ (a dose of 15–5–5 mg/kg once) with MBZ (22 mg/kg) or fenbendazole (50 mg/kg) alone (Miró et al., 2007). Both the US and European formulations of FPP combination tablets were tested on kittens experimentally infected with *Giardia* cysts isolated from a naturally infected cat (Scorza et al., 2006). Kittens were treated daily for 5 consecutive days and stool samples analyzed daily for the presence of *Giardia* cysts. Treatment with the highest dose of FPP, a dose similar to that reported to be effective for the treatment of giardiasis in dogs, give the best intra- and post treatment results. The dosage was well-tolerated with only transient salivation reported (Scorza et al., 2006).

The possible use of the combination of febantel and pyrantel embonate (160, 80, 40, 20 or 10 mg/kg of each drug) for the treatment of giardiasis in mammals, not only dogs and cat, was evaluated using gerbils, a well establish model of giardiasis (Buret et al., 1992), experimentally infected with the *Giardia* isolate WB (Olson et al., 2009). Drugs were administered daily for 3 consecutive days starting from day 5 post-infection and parasite load in the gut was evaluated at day 8. Whereas febantel alone was able to eliminate all trophozoites both at dosage of 160 and 80 mg/kg, combined therapy was effective also at 40 mg/kg indicating a synergistic activity of the two compounds. It is interesting to note that in this study the *Giardia* isolate was known and the authors reported the parasite clearance from the gut of tested animals and not the faecal cyst shedding, clearly showing a giardiacidal effect of the treatment.

In search for alternative natural bio-interventions to ameliorate the treatment of giardiasis, the treatment with anti-giardial compounds combined with natural products was assessed in different animal models of giardiasis.

MTZ in combination with silymarin (a mixture of a flavonoid and phenylpropanoid isolated from an extract of medicinal plant *Silybum marianum*) was tested in asymptomatic dogs naturally infected with *Giardia* (1-3 years of age) and treatment with silymarin alone, MTZ alone or placebo were compared. Even if no significant difference in efficacy between treatment with MTZ with or without silymarin could be reported, combined treatment with silymarin had a positive impact on dog well-being attenuating MTZ side effects ([Chon and Kim, 2005](#)).

Propolis, a bee glue preparation, exerts *in vitro* inhibitory activity on *Giardia* trophozoite growth ([Torres et al., 1990](#)), gaining popularity as alternative for treatment of human giardiasis ([Núñez et al., 2004](#)). The use of propolis and MTZ was evaluated in mice experimentally infected with *Giardia* trophozoites. The count of trophozoites in mice intestine was significantly reduced when the combined therapy was administered, especially after 6 days post infection, if compared to MTZ alone. Propolis alone proved to be a strong enhancer of the immune system, promoting an undesirable inflammatory response in the intestine. Nevertheless, the synergistic effect of both compounds resulted in an immunological balance, especially in terms of the T-lymphocyte profile, that protected the intestinal homeostasis and histological architecture ([Abdel-Fattah and Nada, 2007](#)).

Administration of *Lactobacillus casei* (*L. casei*) has been shown to hamper the adhesion of *Giardia* trophozoites in murine model of giardiasis ([Shukla et al., 2008](#)). Efficacy of the oral administration of the probiotic together with ABZ was also evaluated ([Shukla et](#)

al., 2013). Using Portland-1 trophozoites to infect BALB/c mice, cyst excretion, intestinal trophozoite load, lactobacilli counts and histopathology were recorded throughout the experiment. Co-administration of the probiotic and ABZ exerted a synergistic effect reducing cyst excretion and intestinal trophozoite counts, inhibiting the parasite growth and adherence, likely as consequence of an improved colonization of lactobacilli. Furthermore, *Giardia*-induced damages to the gastrointestinal mucosa were counteracted in the combined therapy (Shukla et al., 2008).

Nanoparticles of silver, chitosan, and curcumin, and their combination, have been also considered as anti-giardial agents. Chitosan is a linear polycationic hetero polysaccharide copolymer obtained from deacetylation of chitin with broad-spectrum antibacterial activity (Martins et al., 2014). Curcumin is a natural polyphenolic compound extracted from the root of *Curcuma longa* with reported activity against different bacteria, viruses, fungi, and parasites (Moghadamtousi et al., 2014). Chitosan and silver nanoparticles were successfully applied as a system for pharmaceutical drug delivery (Marin et al., 2015; Ahmed and Aljaeid, 2016). In the work of Said et al., rats were experimentally infected with *Giardia* cysts, isolated from human stool samples, and treated daily for 8 days with 50 µg of each agent alone (chitosan, curcumin, chitosan nanoparticles, curcumin nanoparticles or silver nanoparticles) or in combination. Therapeutical efficacy was evaluated by fecal shedding of *Giardia* cysts and trophozoites loading in intestinal sections. A complete parasite eradication was reported only in rats administered with the three nanoparticles combination without any reported cytotoxicity and accumulation of silver at safe level in organs (Said et al., 2012). *In vitro* combination assays and the use of different animal models to explore the aforementioned treatment regimens envisage the concrete opportunity to develop, in the future, novel clinical protocols for efficient and safe application of CT against human

giardiasis. However, the inherent problems associated with these kind of studies (e.g. difficult reproducibility due to use of undefined isolates of *Giardia*, not standardized protocols for the evaluation of drug efficacy, different pathophysiology of giardiasis between animals and humans) should be carefully evaluated before translating their results into clinical practice.

3.1.2 Clinical Studies

3.1.2.1. Clinical Series

The use of two or more drugs in combination has become the mainstay in the attempt to overcome resistance/drug tolerance traits in many infectious diseases, including giardiasis as well. Although theoretical advantages to CT have been shown by *in vitro* and animal studies, clinical data are sparse. Observational studies have shown that combining the 5-NI with partner drugs that have different mechanisms of action provides better outcomes. Some of the most common combinations using MTZ are: MTZ-QC (Gillin and Diamond, 1981; Smith et al., 1982; Taylor et al., 1987; Nash et al., 2001; Robertson et al., 2010; Lopez-Velez et al., 2010) MTZ-PRM (Lopez-Velez et al., 2010; Nash, 2013), and MTZ-ABZ (Mørch et al., 2008; Kampitak, 2010; Yadav et al., 2014). An infrequent combinations of MTZ-diloxanide (Mason and Patterson, 1987), MTZ-NTZ (Martínez-Gordillo et al., 2014), MTZ-ABZ-PRM (Lopez-Velez et al., 2010), and MTZ-propranolol have also been reported. For instance, for a patient with MTZ-refractory *Giardia* infection treatment with dl-propranolol, at a dose of 40 mg, and 400 mg of MTZ three times a day for 10 days ended up with the clearance of infection (Popovic' and Milovic', 1990). The combination of TNZ-QC (Lopez-Velez et al., 2010), TNZ-PRM (Lopez-Velez et al., 2010), TNZ-Doxycycline (Mukku et al., 2015) and TNZ-ABZ-PRM-intravenous IgA (Lopez-Velez et al., 2010), as well as unusual combinations like MBZ-PP (Purnomo et al., 1980), PRM-FRZ, and Bacitracin-

PRM ([Nash et al., 2001](#)), have proven successful. Noteworthy, in all these case series treatment schedules lasted longer than usually prescribed.

3.1.2.2. *Randomized clinical trials*

As just presented, some investigators have reported on the successful use of and recommended CT for treatment of non-responders. However, strong evidences, such as those provided by randomized clinical trials (RCTs), are still largely missing. For example, the combination of MTZ and QC has shown the most interesting results, supporting CT in clinical series, but RCTs on its use has not yet been performed. A few as six RCTs on CT have been published so far (Table 2) ([Andrews et al., 1995](#); [Cacopardo et al., 1995](#); [Grant et al., 2001](#); [Pengsaa et al., 2002](#); [Pengsaa et al., 2004](#); [Speich et al., 2013](#)). In one trial bacitracin, bacitracin zinc and neomycin alone were compared to a combination of bacitracin zinc/neomycin ([Andrews et al., 1995](#)). Although a high cure rates was achieved, no synergistic activity was noted between bacitracin zinc and neomycin. In an Italian study, 20 patients, with long lasting symptomatic giardiasis (2-4 months) refractory up to five courses of MTZ, were randomized to receive ABZ (400 mg twice daily 7 days) and the same dose of ABZ plus MTZ (250 mg thrice daily 7 days). Nine out of 10 cases responded to a combination of ABZ-MTZ, while only 2 out of 10 responded to monotherapy with ABZ ([Cacopardo et al., 1995](#)), concluding that ABZ alone is not a therapeutic alternative for treatment MTZ refractory giardiasis. PZQ was found to cause unexpected and statistically significant reductions in the prevalence of *Giardia* infection, when given as a single dose of 5 mg/kg as a part of a *Taenia solium* cysticercosis chemotherapy intervention ([Flisser et al., 1995](#)). When PQ was co-administered with ABZ, it increases the serum level of albendazole sulphoxide, the active metabolite of ABZ ([Homeida et al., 1994](#)). Based on these evidences, two clinical trials were conducted ([Pengsaa et al., 2002](#); [2004](#)). In the

first one, a combined single dose of ABZ 400 mg and PZQ 20 mg/kg achieved a parasitological cure rate of 74.2%; more than ABZ 800 mg as a single dose (50%), but less than TNZ 50 mg/kg as a single dose (92.6%) ([Pengsaa et al., 2002](#)). In the second study, the same combined single dose of ABZ and PZQ was compared with a single dose of 400 mg and the parasitological cure was 60% and 10%, respectively ([Pengsaa et al., 2004](#)). Moreover, the pharmacokinetics of ABZ and albendazole sulphoxide was evaluated, although co-administered of ABZ and PZQ did not influence the compound pharmacokinetics (plasma-concentration–time profile) ([Pengsaa et al., 2004](#)).

In a randomized controlled trial, more than 500 Tanzanian school-aged children (7-15 years old), half of them infected with at least *E. histolytica*/*E. dispar* and/or *Giardia*, were examined to evaluate the efficacy of treatment with single-dose ABZ (400 mg), single-dose NTZ (1,000 mg) and NTZ-ABZ combination (1,000 mg–400 mg), with each drug given separately on two consecutive days; or with placebo ([Speich et al., 2013](#)). Before treatment, the prevalence of children infected with *Giardia* was 16%, with more than 55% having a moderate/heavy infection. At three weeks post-treatment the prevalence of intestinal protozoa infection was even higher and no relevant differences in the cure rate of giardiasis could be reported for each treatment (NTZ-ABZ, 42.1%; single-dose ABZ, 60%; single-dose NTZ, 57.1%) compared to placebo (52 %) ([Speich et al., 2013](#)). A reason for these inconsistent results could be found in the low sensitivity of ether-concentration technique and the analysis of only a single formalin fixed stool sample at the beginning of the trial.

A relatively recently recognized property of wheat germ agglutinin (WGA) is that, at modest concentrations (10–100 µg/mL), it may inhibit *in vitro* *Giardia* excystation as effectively as monoclonal antibodies directed against cyst wall antigens ([Meng et al., 1996](#)) and trophozoite growth in axenic cultures ([Ortega-Barria et al., 1994](#)). In

addition, it is able to reduce cyst passage in mice infected with the protozoan *Giardia muris* (Ortega-Barria et al., 1994). According to these results, a study was performed and published in 2001, involving subjects presenting with giardiasis in Montreal and Lima, Canada and Peru, respectively. This double-masked, placebo-controlled study of dietary supplementation with wheat germ demonstrated that its components, possibly WGA, either alone or in combination with MTZ, may modify the course of giardiasis in humans (Pengsa et al., 2002).

4. The host factor

It has clearly shown that both parasite and host determinants play a role in disease outcomes and recovery (Cotton et al., 2011), making CT just a part in the host-parasite interplay. As stated by Elek in 1956, “*in a way all therapeutic treatments are combined therapy, since the drugs are effective only if body defense of the patient acts in synergy with these drugs*” (Elek, 1956). In this perspective, although treatment failures in *Giardia* infection may appear in patients without any underlying disease (Nash et al., 2001; Lopez-Velez et al., 2010), clinical situations like common variable immunodeficiency (Nash et al., 2001); renal transplant recipients, due to immunosuppressive therapy (Mukku et al., 2015); acquired immunodeficiency syndrome (AIDS) (Nash et al., 2001; Yadav et al., 2014) complex immunodeficiency (Nash et al., 2001); IgA deficiency (Lopez-Velez et al., 2010), acute lymphoid leukaemia (Yadav et al., 2014) and other conditions are not uncommon. In addition, the age, and the nutritional status, the host immune response, as well as a not yet defined genetic makeup, may impact in the host response to anti-giardial drugs (Lopez-Romero et al., 2015).

5. Authors' considerations

Treatment of *Giardia* infections in particular concerning CT, still remains an area of ongoing investigation. In fact, RCTs using CT in individuals failing primary therapy are lacking. Hence, the selection of a combination therapy should be carefully evaluated based on extensive *in vitro* studies, existing animal and human data, meanwhile animal and human RCTs could run in parallel. Compound synergy reported *in vitro* may not necessarily be translated into a clinical benefit, as *in vitro* synergy studies are conducted in well-controlled environments where precise concentrations of multiple antibiotics are tested against known infectious doses of *Giardia*. This scenario can be quite different from clinical, where drug concentrations and *Giardia* trophozoite burdens in patients are unpredictable. Additionally, *in vitro* studies cannot take into account the added contribution of the host immune system. Although, CT is the common approach in clinical for the treatment of persistent refractory giardiasis, a rigorous evaluation to define the more appropriate therapeutical protocol for different CT is still missing and more properly designed RCTs are then required. Indeed, despite promising *in vitro* and case reports observations, no RCT has yet been conducted to evaluate MTZ and QC combination. All the studies reviewed herein represent hypothesis generating results on new treatment combinations. It is important to note that the available data are far to be completed. Incessant research efforts will help to shed light on safety and benefit of new or poorly explored drug combinations for symptomatic giardiasis in first-line monotherapies non-responder patients. In this perspective, *ad-hoc* CT studies should take into consideration several aspects, including the limits imposed by the tolerability and acceptability of multiple therapies and their cost.

It is understandable that physicians have already started to use CT in complicate clinical situations, often with different clinical results. However, lacking RCTs for most

combinations, we urge clinicians to judiciously examine the available data before adopting CT as the standard of care of patients with treatment failures. In the field of CT for clinical giardiasis, still many questions await for an answer: **i)** do we understand the potential pharmacokinetic/pharmacodynamic interactions in CT?; **ii)** is CT really superior to monotherapy?; **iii)** when is CT best used?; **iv)** which patients most likely benefit from CT?; **v)** which combinations work better and which might even be harmful? **vi)** what do we know about CT cost-effectiveness? It is indispensable to clarify all these issues, as well as carry out properly designed RCTs in the near future.

6. Conclusions

To our understanding, CT in giardiasis should be reserved when single primary agents have failed to clear the infection. Despite of this, the efficacy of CT appears encouraging and likely represents the foundation for difficult-to-treat *Giardia* infections now and in the near future. However, it should also be considered that administration of two or three drugs may have more profound physiological consequences, alter the intestinal microbiota and increase drug-related adverse events and healthcare costs. Thus, to optimize the use of already available drugs in combination schedules against *Giardia*, any effort should be done to pursue adequately powered, well-designed, RCTs, which up to this moment are still scarce. Regardless of limitations, present data on CT provide a baseline for future studies in the field of refractory giardiasis management, but further research is required and expected.

Funding

No specific fund supported this work.

Transparency declarations

None to declare.

References

- Abdel-Fattah, N.S., Nada, O.H., 2007. Effect of propolis versus metronidazole and their combined use in treatment of acute experimental giardiasis. *J. Egypt Soc. Parasitol.* 37, (2 Suppl): 691-710.
- Ahmed, T.A., Aljaeid, B.M., 2016. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. *Drug Des. Devel. Ther.* 10, 483-507.
- Andrews, B.J., Mylvaganam, H., Yule, A., 1994. Sensitivity of *Trichomonas vaginalis*, *Tritrichomonas foetus* and *Giardia intestinalis* to bacitracin and its zinc salt *in vitro*. *Trans. R. Soc. Trop. Med. Hyg.* 88, 704-706.
- Andrews, B.J., Panitescu, D., Jipa, G.H., Vasile-Bugarin, A.C., Vasiliu, R.P., Ronnevig, J.R., 1995. Chemotherapy for giardiasis: randomized clinical trial of bacitracin, bacitracin zinc, and a combination of bacitracin zinc with neomycin. *Am. J. Trop. Med. Hyg.* 52, 318-321.
- Andrews, P., Thomas, H., Pohlke, R., Seubert, J., 1983. Praziquantel. *Med. Res. Rev.* 3, 147–200.
- Argüello-García, R., Cruz-Soto, M., Romero-Montoya, L., Ortega-Pierres, G., 2009. *In vitro* resistance to 5-nitroimidazoles and benzimidazoles in *Giardia duodenalis*: variability and variation in gene expression. *Infect. Genet. Evol.* 9, 1057-1064.
- Ballweber, L.R., Xiao, L., Bowman, D.D., Kahn, G., Cama, V.A., 2010. Giardiasis in dogs and cats: update on epidemiology and public health significance. *Trends Parasitol.* 26, 180-189.

Barr, S.C., Bowman, D.D., Frongillo, M.F., Joseph, S.L., 1998. Efficacy of a drug combination of praziquantel, pyrantel pamoate, and febantel against giardiasis in dogs. *Am. J. Vet. Res.* 59, 1134–1136.

Berkman, D.S., Lescano, A.G., Gilman, R.H., Lopez, S.L., Black, M.M., 2002. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. *Lancet* 359, 564-571.

Boreham, P.F.L., Phillips, R.E., Shepherd, R.W., 1987. Heterogeneity of the responses of clones of *Giardia intestinalis* to anti-giardial drugs. *Trans. R. Soc. Trop. Med. Hyg.* 81, 406-407.

Bouzig, M., Halai, K., Jeffreys, D., Hunter PR. 2015. The prevalence of *Giardia* infection in dogs and cats, a systematic review and meta-analysis of prevalence studies from stool samples. *Vet. Parasitol.* 207, 181-202.

Buret, A., Hardin, J.A., Olson, M.E., Gall, D.G., 1992. Pathophysiology of small intestinal malabsorption in gerbils infected with *Giardia lamblia*. *Gastro* 103, 506–513.

Cacopardo, B., Patamia, I., Bonaccorso, V., Di Paola, O., Bonforte, S., Brancati, G., 1995. [Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis]. *Clin. Ter.* 146, 761-767. [Article in Italian].

Campanati, L., Gadelha, A.P., Monteiro-Leal, L.H., 2001. Electron and video-light microscopy analysis of the *in vitro* effects of pyrantel pamoate on *Giardia lamblia*. *Exp. Parasitol.* 97, 9-14.

Celiksöz, A., Aciöz, M., Değerli, S., Cinar, Z., Elaldi, N., Erandaç, M., 2005. Effects of giardiasis on school success, weight and height indices of primary school children in Turkey. *Pediatr. Int.* 47, 567-571.

Chon, S.K., Kim, N.S., 2005. Evaluation of silymarin in the treatment on asymptomatic *Giardia* infections in dogs. *Parasitol. Res.* 97, 445-451.

Cotton, J.A., Beatty, J.K., Buret, A.G., 2011. Host parasite interactions and pathophysiology in *Giardia* infections. *Int. J. Parasitol.* 41, 925-933.

Crouch, A.A., Seow, W.K., Whitman, L.M., Thong, Y.H., 1990. Sensitivity *in vitro* of *Giardia intestinalis* to dyadic combinations of azithromycin, doxycycline, mefloquine, tinidazole and furazolidone. *Trans. R. Soc. Trop. Med. Hyg.* 84, 246-248.

Demirci, M., Delibas, N., Altuntas, I., Oktem, F., Yönden, Z., 2003. Serum iron, zinc and copper levels and lipid peroxidation in children with chronic giardiasis. *J. Health. Popul. Nutr.* 21, 72-75.

Elek, S.D., 1956. Principles and problems of combined antibiotic therapy. *Postgrad. Med. J.* 32, 324–327.

Escobedo, A.A., Almirall, P., Robertson, L.J., Mørch, K., Franco, R.M., Hanevik, K., Cimerman, S., 2010. Giardiasis: The ever present threat of a neglected disease. *Infect. Disord. Drug Targets* 10, 329-348.

Escobedo, A.A., Arencibia, R., Vega, R.L., Almirall, P., Rodríguez-Morales, A.J., Alfonso, M., 2015. A bibliometric study of international scientific productivity in giardiasis covering the period 1971–2010. *J. Infect. Dev. Ctries.* 9, 076-086.

Escobedo, A.A., Cimerman, S., 2007. Giardiasis: A pharmacotherapy review. *Expert Opin. Pharmacother.* 8, 1885-1902.

Flisser, A., Sarti, E., Sarti, R., Schantz, P.M., Valencia, S., 1995. Effect of praziquantel on protozoan parasites. *Lancet* 345, 316–317.

Gardner, T.B., Hill, D.R., 2001. Treatment of giardiasis. Clin. Microbiol. Rev. 14, 114-128.

Giangaspero, A., Traldi, G., Paoletti, B., Traversa, D., 2002. Bianciardi P. Efficacy of pyrantel embonate, febantel and praziquantel against *Giardia* species in naturally infected adult dogs. Vet. Rec. 150, 184-186.

Gillin, F.D., Diamond, L.S., 1981. Inhibition of clonal growth of *Giardia lamblia* and *Entamoeba histolytica* by metronidazole, quinacrine, and other antimicrobial agents. J. Antimicrob. Chemother. 8, 305-316.

Grant, J., Mahanty, S., Khadir, A., MacLean, J.D., Kokoskin, E., Yeager, B., Joseph L., Diaz, J., Gotuzzo, E., Mainville, N., Ward, B.J., 2001. Wheat germ supplement reduces cyst and trophozoite passage in people with giardiasis. Am. J. Trop. Med. Hyg. 65; 705-710.

Hahn, J., Seeber, F., Kolodziej, H., Ignatius, R., Laue, M., Aebischer, T., Klotz, C., 2013. High sensitivity of *Giardia duodenalis* to tetrahydrolipstatin (orlistat) *in vitro*. PLoS One 8, e71597.

Hausen, M.A., Menna-Barreto, R.F., Lira, D.C., de Carvalho, L., Barbosa, H.S., 2011. Synergic effect of metronidazole and pyrantel pamoate on *Giardia lamblia*. Parasitol. Int. 60, 54-58.

Heyman, M.L., Williams, R.L., 2011. Ensuring global access to quality medicines: role of the US pharmacopeia. J. Pharm. Sci. 100, 1280–1287.

Hoffman, P.S., Sisson, G., Croxen, M.A., Welch, K., Harman, W.D., Cremades, N., Morash, M.G., 2007. Antiparasitic drug nitazoxanide inhibits the pyruvate

oxidoreductases of *Helicobacter pylori*, selected anaerobic bacteria and parasites, and *Campylobacter jejuni*. Antimicrob. Agents Chemother. 51, 868-876.

Homeida, M., Leahey, W., Copeland, S., Ali, M.M., 1994. Harron DW. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann. Trop. Med. Parasitol. 88, 551-559.

Jiménez-Cardoso, E., Flores-Luna, A., Pérez-Urizar, J., 2004. *In vitro* activity of two phenyl-carbamate derivatives, singly and in combination with albendazole against albendazole-resistant *Giardia intestinalis*. Acta Trop. 92, 237-244.

Kampitak, T., 2010. Selective immunoglobulin M deficiency in a patient with refractory giardiasis. J. Investig. Allergol. Clin. Immunol. 20, 358-360.

Katiyar, S.K., Visvesvara, G.S, Edlind, T.D., 1995. Comparisons of ribosomal RNA sequences from amitochondrial protozoa: implications for processing, mRNA binding and paromomycin susceptibility. Gene 152, 27-33.

Kopp, S.R., Kotze, A.C., McCarthy, J.S., Traub, R.J., Coleman, G.T., 2008. Pyrantel in small animal medicine: 30 years on. Vet. J. 178, 177-184.

Lalle, M., 2010. Giardiasis in the post genomic era: Treatment, drug resistance and novel therapeutic perspectives. Infect. Disord. Drug Targets 10, 283-294.

Leitsch, D., 2015. Drug resistance in the microaerophilic parasite *Giardia lamblia*. Curr. Trop. Med. Rep. 2, 128-135.

Leitsch, D., Burgess A.G., Dunn, L.A., Krauer, K.G., Tan, K., Duchêne, M., Upcroft P., Eckmann, L., Upcroft, J.A., 2011. Pyruvate:ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole activation while flavin metabolism is linked

to 5-nitroimidazole resistance in *Giardia lamblia*. J. Antimicrob. Chemother. 66, 1756-1765.

Leitsch, D., Schlosser, S., Burgess, A., Duchêne, M., 2012. Nitroimidazole drugs vary in their mode of action in the human parasite *Giardia lamblia*. Int. J. Parasitol. Drugs Drug Resist. 2, 166-170.

Lopez-Romero, G., Quintero, J., Astiazarán-García, H., Velazquez, C., 2015. Host defences against *Giardia lamblia*. Parasite Immunology 37, 394–406.

Lopez-Velez, R., Batlle, C., Jiménez, C., Navarro, M., Norman, F., Perez-Molina, J., 2010. Short course combination therapy for giardiasis after nitroimidazole failure. Am. J. Trop. Med. Hyg. 83, 171-173.

MacDonald, L.M., Armson, A., Thompson, A.R., Reynoldson, J.A., 2004. Characterisation of benzimidazole binding with recombinant tubulin from *Giardia duodenalis*, *Encephalitozoon intestinalis*, and *Cryptosporidium parvum*. Mol. Biochem. Parasitol. 138, 89- 96.

McDowall, R.M., Peregrine, A.S., Leonard, E.K., Lacombe, C., Lake, M., Rebelo, A.R., Cai, H.Y., 2011. Evaluation of the zoonotic potential of *Giardia duodenalis* in fecal samples from dogs and cats in Ontario. Can. Vet. J. 52, 1329-1333.

Marin, S., Vlasceanu, G.M., Tiplea, R.E., Bucur, I.R., Lemnaru, M., Marin, M.M., Grumezescu, A.M., 2015. Applications and toxicity of silver nanoparticles: a recent review. Curr. Top. Med. Chem. 15, 1596-1604.

Martínez-Gordillo, M.N., González-Maciél, A., Reynoso-Robles, R., Montijo-Barrios, E., Ponce-Macotela, M., 2014. Intraepithelial *Giardia intestinalis*: a case report and literature review. Medicine (Baltimore); 93, e277.

Martins, A.F., Facchi, S.P., Follmann, H.D., Pereira, A.G., Rubira, A.F., Muniz, E.C., 2014. Antimicrobial activity of chitosan derivatives containing N-quaternized moieties in its backbone: a review. *Int. J. Mol. Sci.* 15, 20800-20832.

Mason, P.R., Patterson, B.A., 1987. Epidemiology of *Giardia lamblia* infection in children: cross-sectional and longitudinal studies in urban and rural communities in Zimbabwe. *Am. J. Trop. Med. Hyg.* 37, 277-282.

Mc Kellar, Q.A., Scott, E.W., 1990. The benzimidazole anthelmintics, a review. *J. Vet. Pharmacol. Ther.* 13, 223-247.

Meng, T.C., Hetsko, M.L., Gillin, F.D., 1996. Inhibition of *Giardia lamblia* excystation by antibodies against cyst walls and by wheat germ agglutinin. *Infect. Immun.* 64, 2151-2157.

Miró, G., Mateo, M., Montoya, A., Vela, E., Calonge, R., 2007. Survey of intestinal parasites in stray dogs in the Madrid area and comparison of the efficacy of three anthelmintics in naturally infected dogs. *Parasitol. Res.* 100, 317-320.

Moghadamtousi S.Z., Kadir H.A., Hassandarvish P., Tajik H., Abubakar S., Zandi K. 2014. A review on antibacterial, antiviral, and antifungal activity of curcumin. *Biomed. Res. Int.* 2014, 186864.

Montoya, A., Dado, D., Mateo, M., Espinosa, C., Miró, G., 2008. Efficacy of Drontal® flavour Plus (50 mg praziquantel, 144 mg pyrantel embonate, 150 mg febantel per tablet) against *Giardia* sp. in naturally infected dogs. *Parasitol. Res.* 103, 1141-1144.

Mørch, K., Hanevik, K., Robertson, L.J., Strand, E.A., Langeland, N., 2008. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. *J. Infect.* 56, 268-273.

Morgan, U.M., Reynoldson, J.A, Thompson, R.C.A., 1993. Activities of several benzimidazoles and tubulin inhibitors against *Giardia* spp. *in vitro*. Antimicrob. Agents Chemother. 37, 328-331.

Mukku, K.K., Raju, S., Yelanati, R., 2015. Refractory giardiasis in renal transplantation: a case report. Nephrology (Carlton) 20, 44.

Müller, J., Ley, S., Felger, I., Hemphill, A., Müller, N., 2008. Identification of differentially expressed genes in a *Giardia lamblia* WB C6 clone resistant to nitazoxanide and metronidazole. J. Antimicrob. Chemother. 62, 72-82.

Müller, J., Rout, S., Leitsch, D., Vaithilingam, J., Hehl, A., Norbert, M.N., 2015. Comparative characterisation of two nitroreductases from *Giardia lamblia* as potential activators of nitro compounds. Int. J. Parasitol. Drugs Drug Resist. 5, 37–43.

Müller, J., Rühle, G., Müller, N., Rossignol, J.F., Hemphill, A., 2006. *In vitro* effects of thiazolides on *Giardia lamblia* WB clone C6 cultured axenically and in coculture with Caco2 cells. Antimicrob. Agents Chemother. 50, 162-170.

Müller, J., Schildknecht, P., Müller, N., 2013. Metabolism of nitro drugs metronidazole and nitazoxanide in *Giardia lamblia*: characterization of a novel nitroreductase (GlnR2). J. Antimicrob. Chemother. 68, 1781–1789.

Nash, T.E., 2013. Unraveling how *Giardia* infections cause disease. J. Clin. Invest. 123, 2346-2347.

Nash, T.E., Ohl, C.A., Thomas, E., Subramanian, G., Keiser, P., Moore, T.A., 2001. Treatment of patients with refractory giardiasis. Clin. Infect. Dis. 33, 22-28.

Núñez, F.A., Escobedo, A., Finlay, C.M., 2004. Eficacia de varios esquemas de tratamiento para la infección por *Giardia lamblia* en niños. Rev. Panamericana Infectol. 6, 17-20.

Olivares, J.L., Fernández, R., Fleta, J., Ruiz, M.Y., Clavel, A., 2002. Vitamin B12 and folic acid in children with intestinal parasitic infection. J. Am. Coll. Nutr. 21, 109-113.

Olson, M.E., Heine, J., 2009. Synergistic effect of febantel and pyrantel embonate in elimination of *Giardia* in a gerbil model. Parasitol. Res. 105, Suppl 1, S135-S140.

Ortega-Barria, E., Ward, H.D., Keutsch, G.T., Pereira, M.E.A., 1994. Growth inhibition of the intestinal parasite *Giardia lamblia* by a dietary lectin is associated with arrest of the cell cycle. J. Exp. Med. 94, 2283–2288.

Paget, T.A., Jarroll, E.L., Manning, P., Lindmark, D.G., Lloyd, D., 1989. Respiration in the cyst and trophozoite forms of *Giardia muris*. J. Gen. Microbiol. 135, 145-154.

Payne, P.A., Ridley, R.K., Dryden, M.W., Bathgate, C., Milliken, G.A., Stewart, P.W., 2002. Efficacy of a combination febantel–praziquantel–pyrantel product, with or without vaccination with a commercial *Giardia* vaccine, for treatment of dogs with naturally occurring giardiasis. J. Am. Vet. Med. Assoc. 220, 330–333.

Pengsaa, K., Limkittikul, K., Pojjaroen-anant, C., Lapphra, K., Sirivichayakul, C., Wisetsing, P., Nanthaa-aree, P., Chanthavanich, P., 2002. Single-dose therapy for giardiasis in school-age children. Southeast Asian J. Trop. Med. Public Health 33, 711-717.

Pengsaa, K., Na-Bangchang, K., Limkittikul, K., Kabkaew, K., Lapphra, K., Sirivichayakul, C., Wisetsing, P., Pojjaroen-Anant, C., Chanthavanich, P., Subchareon,

A. 2004. Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with *Giardia intestinalis*. Ann. Trop. Med. Parasitol. 98, 349-357.

Persson, R., Wensaas, K-A., Hanevik, K., Eide, G.E., Langeland, N., Rortveit, G., 2015. The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection. BMC Gastroenterology 15, 66.

Popovic', O.S., Milovic', V., 1990. Propranolol and metronidazole for the treatment of metronidazole-resistant giardiasis. J. Clin. Gastroenterol. 12, 604-605.

Purnomo, Partono, F., Soewarta, A., 1980. Human intestinal parasites in Karakuak, West Flores, Indonesia and the effect of treatment with mebendazole and pyrantel pamoate. Southeast Asian J. Trop. Med. Public Health 11, 324-331.

Quihui-Cota, L., Astiazarán-García, H., Valencia, M.E., Morales-Figueroa, G.G., Lopez-Mata, M.A., Vazquez Ortiz, F., 2008. Impact of *Giardia intestinalis* on vitamin a status in schoolchildren from northwest Mexico. Int. J. Vitam. Nutr. Res. 78, 51-56.

Robertson, L.J., Hanevik, K., Escobedo, A.A., Mørch, K., Langeland, N., 2010. Giardiasis – why do the symptoms sometimes never stop? Trends Parasitol. 26, 75-82.

Ryan, U., Cacciò, S.M., 2013. Zoonotic potential of *Giardia*. Int. J. Parasitol. 43, 943-956.

Said, D.E., Elsamad, L.M., Gohar, Y.M., 2012. Validity of silver, chitosan, and curcumin nanoparticles as anti-*Giardia* agents. Parasitol. Res. 111, 545-554.

Scorza, A.V., Radecki, S.V., Lappin, M.R., 2006. Efficacy of a combination of febantel, pyrantel, and praziquantel for the treatment of kittens experimentally infected with *Giardia* species. J. Feline Med. Surg. 8, 7-13.

Shepherd, R.W., Boreham, P.F., 1989. Recent advances in the diagnosis and management of giardiasis. Scand. J. Gastroenterol. 169, Suppl. 60-64.

Shukla, G., Devi, P., Sehgal, R., 2008. Effect of *Lactobacillus casei* as a probiotic on modulation of giardiasis. Dig. Dis. Sci. 53, 2671-2679.

Shukla, G., Kaur, H., Sharma L., 2013. Comparative therapeutic effect of probiotic *Lactobacillus casei* alone and in conjunction with antiprotozoal drugs in murine giardiasis. Parasitol. Res. 112, 2143-2149.

Smith, P.D., Gillin, F.D., Spira, W.M., Nash, T.E., 1982. Chronic giardiasis: studies on drug sensitivity, toxin production, and host immune response. Gastroenterology 83, 797-803.

Speich, B., Marti, H., Ame, S.M., Ali, S.M., Bogoch, I.I., Utzinger, J., Albonico, M., Keiser, J., 2013. Prevalence of intestinal protozoa infection among school-aged children on Pemba Island, Tanzania, and effect of single-dose albendazole, nitazoxanide and albendazole-nitazoxanide. *Parasit. Vectors* 6, 3.

Taylor, G.D., Wenman, W.M., Tyrrell, D.L., 1987. Combined metronidazole and quinacrine hydrochloride therapy for chronic giardiasis. C.M.A.J. 136, 1179-1180.

Thompson, R.C., 2004 The zoonotic significance and molecular epidemiology of *Giardia* and giardiasis. Vet. Parasitol. 126, 15–35.

Torres, D., Hollands, I., Palacios, E., 1990. Efecto de un extracto alcohólico de propóleos sobre el crecimiento de *Giardia lamblia* *in vitro*. Rev. Cubana Cienc. Vet. 21, 15 -20.

Upcroft, J.A., Campbell, R.W., Upcroft, P., 1996. Quinacrine-resistant *Giardia duodenalis*. Parasitology 112, 309–313.

Upcroft, J.A., Mitchell, R., Chen, N., Upcroft, P., 1996. Albendazole resistance in *Giardia* is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in β -tubulin. Microb. Drug Resist. 2, 303-308.

Upcroft, P., Upcroft, J.A., 2001. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin. Microbiol. Rev. 14, 150-164.

Uzlikova, M., Nohynkova, E., 2014. The effect of metronidazole on the cell cycle and DNA in metronidazole-susceptible and –resistant *Giardia* cell lines. Mol. Biochem. Parasitol. 198, 75-81.

Velázquez-Olvera, S., Salgado-Zamora, H., Jiménez-Cardoso, E., Campos-Aldrete, M.E., Pérez-González, C., Ben Hadda, T., 2016. *In vitro* anti-*Giardia lamblia* activity of 2-aryl-3-hydroxymethyl imidazo[1,2-a]pyridines and -pyrimidines, individually and in combination with albendazole. Acta Trop. 155, 6-10.

Yadav, P., Tak, V., Mirdha, B.R., Makharia, G.K., 2014. Refractory giardiasis: a molecular appraisal from a tertiary care centre in India. Indian J. Med. Microbiol. 32, 378-382.

Table 1. Mechanisms of resistance in *Giardia*

Pharmacologic group	Drug	Main mode of action	Major resistance mechanism	Reference
Acridine derivatives	Quinacrine	Inhibition of oxygen consumption, binding to DNA, plasma membrane damage.	Decreased entry of drug.	Lalle, 2010; Paget et al., 1989; Upcroft et al., 1996
5-Nitroimidazole compounds	Metronidazole (MTZ) Tinidazole Secnidazole Ornidazole	Reduction MTZ nitro group to nitroso radical highly reactive with DNA, free and protein cysteines, interfering with several biological processes. Reduction is mediated by pyruvate:ferredoxin oxidoreductase (PFOR), thioredoxin reductase (TRxR) and NADPH oxidase. Similar mechanism proposed for the other drug.	MTZ resistance associate to inactivation of the PFOR/ferredoxin pathway, downregulation of nitroreductase 1 (NTR1) and upregulation of (NTR2).	Lalle, 2010; Upcroft and Upcroft, 2001; Leitsch et al., 2011; Leitsch et al., 2012; Muller et al., 2013; Uzlikova and Nohynkova, 2014
Nitrofuran derivatives	Furazolidone	Similar to 5-nitroimidazoles. Drug activation associated to NADH oxidase activity.	Decreased entry of drug or increased defend mechanisms against toxic radicals (increased level of thiol-cycling enzymes).	Lalle, 2010; Leitsch et al., 2015
Aminoglycosides	Paromomycin	Inhibition of protein synthesis.	No resistant parasite as been yet isolated.	Lalle, 2010; Katiyar et al., 1995
Benzimidazole compounds	Albendazole Mebendazole	Binding to β -tubulin and inhibition of cytoskeleton polymerization.	Not yet defined, but in resistant strain rearrangements of chromosomes and cytoskeleton, and alteration of gene expression (VSPs, β -giardin) has been	Morgan et al., 1993; Upcroft, et al., 1996; MacDonald et al., 2004; Argüello-García et al., 2009

			reported.	
5-nitrothiazolyl derivatives	Nitazoxanide	Noncompetitive inhibition of the PFOR and nitroreductases, alterations on the ventral disk and surface membrane.	Activation of a general stress response mechanism partially overlapping with MTZ resistance.	Müller, et al., 2006; Hoffman et al., 2007; Muller et al., 2007; Muller et al., 2008
Polypeptide antibiotic	Bacitracin Zinc	In bacteria, interferes with dephosphorylation step in cell membrane synthesis.	Not yet reported.	Andrews et al., 1995; Andrews et al., 1994; Gardner and Hill, 2001

PFOR: enzyme pyruvate:ferredoxin oxidoreductase

Table 2. Comparative RCTs assessing the benefit of CT compared with monotherapy for *Giardia* infections

Authors	Country	Combination therapy (dosage)	Number of cases treated	Parasitological cure rate	Comparators (dosage)	Number of cases treated	Efficacy of comparators	Comments on combination therapy
Andrews et al. 1995	Romania	Bacitracin zinc with neomycin (60,000 U - 60,000 U), two times daily for 10 days.	16	87.5%	Bacitracin (120 000 U)	16	87.5%	Few side effects involving gastrointestinal upset. No synergistic activity was noted between bacitracin zinc and neomycin.
					Bacitracin zinc (120 000 U)	19	94.7%	
					Neomycin (120 000 U)	22	86.4%	
					All, two times daily for 10 days.			
Cacopardo et al. 1995	Italy	ABZ-MTZ (400 mg/day- 250 mg thrice a day). Both for 7 days	10	90%	ABZ (400 mg) daily for 7 days	10	20%	All patients reported the disappearance of clinical symptoms, as well as no side effects. Diarrhoea was reduced already at day 2 post therapy start. Only 1 patient reported after 4 week symptoms relapse.

Grant et al-2001	Canada and Peru	Asymptomatic subjects (WG 2 g, 3 times a day) for 10 days, followed by MTZ (250 mg 3 times a day) for 7 days.).	11	63.6	Placebo (cornstarch, 2 g, 3 times a day) for 10 days, followed by MTZ (250 mg 3 times a day) for 7 days.).	13	76.9	There were no clinically important differences between those receiving supplemental WG or placebo. However, symptoms appear to have resolved more rapidly in the subjects taking WG in addition to MTZ.
		Symptomatic patients (MTZ, 250 mg 3 times a day, plus WG for 7 days.)	21	90.4	Symptomatic patients (MTZ, 250 mg 3 times a day, plus placebo for 7 days.)	17	94.1	
Pengsaa et al. 2002	Thailand	ABZ-PZQ (400 mg-20 mg/kg) SD	31	74.2%	ABZ 800 mg SD	26	50%	Though several episodes of side-effects were observed, they were mild, except for 2 cases of abdominal pain and nausea/dizziness that needed medication.
					TNZ 50 mg/kg SD	27	92.6%	
Pengsaa et al. 2004	Thailand	ABZ-PZQ (400 mg-20 mg/kg) SD	10	40%	ABZ	10	10%	No adverse effects were noted in any of the

					(400 mg), SD			<p>children investigated.</p> <p>No significant pharmacokinetic interaction between the ABZ and PZQ was demonstrated. The pharmacokinetics of albendazole sulphoxide, the active metabolite of ABZ, was similar whether ABZ was given alone or in combination with PZQ.</p>
Speich et al. 2013	Tanzania	NTZ-ABZ (1,000 mg–400 mg), with each drug given separately on two consecutive days.	19	42.1%	ABZ (400 mg), SD NTZ (1,000 mg), SD Placebo	25 21 25	60% 57.1% 52 %	<p>The combination of the two drugs ABZ-NTZ has not got sufficient efficacy; in fact, curiously was less than placebo.</p>

Rebuttal to reviewer comments

- This is a competent review of in vitro and in vivo combination treatment in animals and human for Giardia. The studies reviewed are obviously varied in quality and methodology. There is some attempt at criticism of some of the papers but I think a heavier hand here is needed. For instance, many of the drug studies in vitro use adherence of parasite as an end point, where the best assays assess include cidal effects. In the same vein, many of the human studies use stool examination, which is the traditional manner of diagnosis, but performed 7-14 days after completing treatment. Since giardiasis is a relapsing infection, this is not optimal. The studies in dogs and cats are nice, but there needs to be mention that these are really different organisms biologically from human isolates so that what is effective in animals may or may not be effective in human infections.

Answer: We thank the reviewer for its appreciation on the work done in this review.

We agree with the general comment and a sentence was included at the beginning of **Result section**: "It should be taken into account that, covering a period of almost 40 years, the reviewed studies varied in terms of quality and methodologies, especially in evaluating drug treatment outcomes. In this perspective, a rigorous comparison of experimental data could not be feasible."

Concerning the studies in animal, at the end of paragraph 3.1.1.1 we already and clearly stated that. "....the inherent problems associated with these kind of studies (e.g. difficult reproducibility due to use of undefined isolates of Giardia, not standardized protocols for the evaluation of drug efficacy, different pathophysiology of giardiasis between animals and humans) should be carefully evaluated before translating their results into clinical practice"

- In paragraph 3.1.1.2, the authors state that pets may represent a significant reservoir for their owners. This is a bit too definitive and not proven. In some reviews there are blanket statements that giardiasis is an enzootic, and in fact the admixture of genotypes in animals are very suggestive. However, the data are not definitive. Although some animals harbor the same genotype as found in humans suggesting cross infections, in fact the dog isolate, for instance, is rarely found in man and there has been no believable epidemics originating from a dog or cat into humans. The numbers of kittens and puppies with giardiasis is very large and yet one doesn't see their owners and family with giardiasis.

Answer: In agreement with the reviewer, the sentence has been modified including new references: "Several studies reported on high prevalence of Giardia in stool samples of companion animals (i.e. cats and dogs) (Bouzid et al., 2015). Pets are prevalently infected with host-specific assemblages (C and D in dogs, F in cats), but the zoonotic A and B assemblages were also reported in several settings, and may prevail in environments commonly contaminated with cysts from the feces of humans or other animals (Thompson, 2004; Ballweber et al., 2010). Although their role as reservoir and the associated risk for their owners is unclear, their treatment to potentially reduce the risk of transfer to human beings cannot be ignored."

- In paragraph 3.1.2.1 the first clinical use of MTX and Qc was in the Smith et al paper that is in the bibliography and mentioned elsewhere. It should be included here. There is also a recent paper by Meltzer et al (Emerging Infect Dis 20: 1742, 2014) that gives their experience in Metaz and quinacrine.

Answer:We thanks the reviewer to have noticed the accidental loss of the reference “Smith et al 1982”. In the 12 cases of refractory giardiasis reported in Meltzer et al., each second line drug was not administered in combination with MTZ but following MTZ treatment failure. For this reason the paper was not included.

- In paragraph 3.1.2.2 the authors state that there is no evidence for the efficacy of combined treatment and MTZ and quinacrine. Yes there are no randomized trials but cure of a patient who has had giardiasis for 15 years after many courses of available drugs, is reasonable evidence when repeatable, although certainly not definitive. It is just that there are different degrees of evidence.

Answer:Our opinion on MTZ-QC efficacy was probably misunderstood. For this reason we have modified the initial statement on paragraph 3.1.2.2 as follow: “As just presented, some investigators have reported on the successful use of and recommended CT for treatment of non-responders. However, strong evidences, such as those provided by randomized clinical trials (RCTs), are still largely missing. For example, the combination of MTZ and QC has shown the most interesting results, supporting CT in clinical series, but RCTs on its use has not yet been performed”.